Telegraph pharma and chemicals
The latest news, analysis and information about the Pharmaceuticals and Chemicals industries.
Updated: 53 min 41 sec ago
GlaxoSmithKline to buy Cellzome for £61m
GlaxoSmithKline, the UK's biggest drug company, is to buy a leading protein technology company in which it already owns a 20pc stake.
Categories: Chemicals, Pharmaceuticals
Warren Buffett backs Coty's $10.7bn bid for perfume maker Avon
Billionaire investor Warren Buffett is backing an improved $10.7bn (£6.62bn) offer from perfume maker Coty for Avon in a move that increases the pressure on the troubled door-to-door cosmetics seller.
Categories: Chemicals, Pharmaceuticals
Glaxo makes $2.6bn hostile bid for Human Genome
GlaxoSmithKline has gone hostile with its $2.6bn (£1.6bn) offer for US Human Genome Sciences - bypassing management and taking its bid directly to shareholders.
Categories: Chemicals, Pharmaceuticals
Smith & Nephew boosted by demand for replacement knees
Medical devices company Smith & Nephew was the biggest riser in the FTSE 100 on Thursday after an increase in demand for its replacement knees fuelled a rise in profits.
Categories: Chemicals, Pharmaceuticals
Novartis to buy dermatology company Fougera for $1.5bn
Swiss drugmaker Novartis has sealed a deal to buy Fougera Pharmaceuticals, a maker of generic dermatology products, for $1.53bn in cash.
Categories: Chemicals, Pharmaceuticals
Questor share tip: GlaxoSmithKline remains the pharma to own
Last week's first-quarter results from pharmaceuticals group GlaxoSmithKline were below market expectations. However, there are no changes to full-year guidance.
Categories: Chemicals, Pharmaceuticals
Shareholder: GlaxoSmithKline offer is bitter pill
GlaxoSmithKline's attempt to land its biggest acquisition since 2009 has suffered a blow after a top shareholder in Human Genome Sciences said the British group's offer was "a steal".
Categories: Chemicals, Pharmaceuticals
Questor share tip: Croda scrubs up well, but is a hold
As usual, speciality chemicals company Croda has delivered in its latest update - but the shares moved lower as well-rewarded investors banked some gains.
Categories: Chemicals, Pharmaceuticals
David Brennan steps down as AstraZeneca profits tumble
David Brennan's resignation after six years at the helm of AstraZeneca, alongside a 38pc drop in first-quarter profits, sent shares the pharmaceutical giant tumbling 6pc.
Categories: Chemicals, Pharmaceuticals
AstraZeneca shareholders see £2.2bn wiped off value after chief David Brennan steps down
AstraZeneca shareholders saw more than £2.2bn wiped off the pharmaceutical group's value as a boardroom shake-up following a period of investor unrest led to the abrupt departure of chief David Brennan.
Categories: Chemicals, Pharmaceuticals
AstraZeneca will need more than the placebo effect to placate investors
Sometimes the drugs just don't work.
Categories: Chemicals, Pharmaceuticals
AstraZeneca is in need of radical surgery after chief David Brennan retires
Boss' departure could herald dramatic change at troubled drug maker.
Categories: Chemicals, Pharmaceuticals
Profile: David Brennan
David Brennan announced this morning that he was to step down after six years in charge of pharmaceutical giant AstraZeneca, just as it posted a 38pc drop in first-quarter profits. We take a look at his career to date.
Categories: Chemicals, Pharmaceuticals
Former Healthcare Locums chairman Alan Walker denies 'sexual impropriety' with Kate Bleasdale
Alan Walker, former chairman of Healthcare Locums, has vigorously denied allegations by chief executive Kate Bleasdale that she was wrongfully sacked and that he touched her breast.
Categories: Chemicals, Pharmaceuticals
Glaxo says it's 'compelling owner' of Human Genome Sciences as sales disappoint
GlaxoSmithKline has stressed that it is the "compelling owner" of Human Genome Sciences, which last week rebuffed a $2.6bn (£1.6bn) bid from the British drug giant.
Categories: Chemicals, Pharmaceuticals
Questor shares tip: BTG's Varisolve clears another hurdle
Many investors will tell you that investing in the high-octane biotechnology sector can be a recipe for a ticket to the poorhouse.
Categories: Chemicals, Pharmaceuticals
AstraZeneca to buy gout drug maker Ardea Biosciences for $1.26bn
AstraZeneca has moved to boost its slim pipeline of new drugs by agreeing a $1.26bn (£783m) deal to buy Californian biotechnology group Ardea Biosciences.
Categories: Chemicals, Pharmaceuticals
AstraZeneca seeks a remedy for its patent pain
CEO David Brennan could need a tablet when he unveils first-quarter results.
Categories: Chemicals, Pharmaceuticals
GlaxoSmithKline sells clutch of drugs for £164m to Aspen
GlaxoSmithKline has offloaded a clutch of its over-the-counter drugs in a £164m deal, but has still been unable to sell its weight loss treatment, Alli.
Categories: Chemicals, Pharmaceuticals
Warren Buffett's biggest buys: in pictures
Last year, Warren Buffett completed one of his largest acquisitions by agreeing to pay $9bn in cash for US chemicals maker Lubrizol. Here, we look at the billionaire investor's most expensive purchases.
Categories: Chemicals, Pharmaceuticals
The Bottom Line:If Mr Cable has his way...
"If Mr Cable had his way, all the big banks would be broken up and bonuses would be virtually eliminated - a sure-fire way in my view of guaranteeing an end to the UK’s ability to compete as an international financial centre. Let’s not forget that this is a man who is on record as saying that everyone who works in a bank has an ‘aristocratic lifestyle’ clearly demonstrating his lack of understanding of the sector." A tough line on bankers’ bonuses could make a brain drain of financial talent a distinct possibility, warns Paul Marsden. Read more